Protalix Biotherapeutics Inc (PLX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

• Price: $3.02
• Market Cap: $243.68M
• P/E Ratio: 37.88
• EPS: $0.08
• 52-Week High: $3.19
• 52-Week Low: $1.32

Market Sentiment

Protalix Biotherapeutics Inc currently has a Bullish sentiment score of 0.20.

About Protalix Biotherapeutics Inc

Protalix Biotherapeutics Inc. is an innovative biopharmaceutical company based in Karmiel, Israel, that specializes in the development and commercialization of recombinant therapeutic proteins through its unique ProCellEx plant cell-based expression system. Focused on addressing unmet medical needs, Protalix is advancing treatments for various conditions in markets including Israel, Brazil, and Latin America. Its commitment to biotechnology and strategic international expansion positions Prot...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Protalix Biotherapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does PLX pay dividends?

Protalix Biotherapeutics Inc (PLX) does not currently pay a regular dividend.

What is PLX's P/E ratio?

Protalix Biotherapeutics Inc has a price-to-earnings (P/E) ratio of 37.88.

What is PLX's market cap?

Protalix Biotherapeutics Inc (PLX) has a market capitalization of $243.68M with a current stock price of $3.02.